On Monday, March 7, 2016, Congressman Lloyd Doggett, D-Texas, issued a statement in support of the recent Knowledge Ecology International (KEI) and Union for Affordable Cancer Treatment (UACT) request that the National Institutes of Health (NIH) authorize the generic production of an expensive prostate cancer drug in order to curb an excessive and discriminatory price in the United States.
The World Intellectual Property Organization’s (WIPO) Twenty-Second session of the Standing Committee on the Law of Patents (SCP) will be convened from 27 July 2015 to 31 July 2015 in Geneva, Switzerland. For consideration of the Committee, the Group of Latin American and Caribbean Countries (GRULAC) have submitted a proposal entitled, Revision of 1979 WIPO Model Law for Developing Countries on Inventions (SCP/22/5). Continue Reading
In discussions at the June 2015 WTO TRIPS Council on the role of intellectual property in financing innovation, India underscored its commitment to the principle of de-linkage by stating,
Innovation should not be viewed within the narrow prism of intellectual property monopolies but framed within a holistic, knowledge ecosystem that includes open innovation, open knowledge approaches and de-linkage of R&D costs from product prices
On Friday, 8 May 2015, the World Health Organization (WHO) unveiled its 19th WHO Model of Essential Medicines (April 2015).
With respect to cancer drugs (Section 8.2, Cytoxic and Adjuvant Medicines), the Executive Summary noted that the Committee added 16 new medicines.
TRIPS Council (October 2014): India calls for de-linkage and innovation inducement prizes at WTO discussions on IP & innovation
In advance of the World Trade Organization’s October 2014 session of the TRIPS Council, the European Union, Switzerland and the United States made a written request to the TRIPS Council to discuss “Intellectual Property and Innovation: Promoting Awareness; Case Studies” under agenda item 12. This marked the 7th time that the United States tabled an item to the TRIPS Council relating to intellectual property or innovation.
In the context of these October 2014 discussions of Intellectual Property and Innovation, the Government of India delivered the following intervention asserting that,
NIH rejects March-In petition, also rejects proposed rules on pricing of and access to government funded inventions
In a decision dated November 1, 2013, and signed by NIH Director Francis Collins, the NIH has rejected the 2012 petition to the NIH to uses its powers under the Bayh-Dole Act to protect U.S. consumers from high prices and restrictive licensing of NIH funded inventions.
White House refuses FOIA request for documents on country positions on transparency of ACTA negotiations
On June 2, 2010, KEI submitted a FOIA request to the White House Office of the United States Trade Representative (USTR). The request covered:
The language in S. 3187, calling for National Academies evaluation of Medical Innovation inducement prizes
S.3187 Food and Drug Administration Safety and Innovation Act (Engrossed in Senate [Passed Senate] – ES)SEC. 906. INDEPENDENT STUDY ON MEDICAL INNOVATION INDUCEMENT MODEL.
Statement of Thailand to EB 126 (Jan 2010) on public health, innovation and intellectual property
The following statement was delivered by Thailand on Tuesday, 19 January 2010 during the discussion of agenda item 4.3 on public health, innovation and intellectual property. This statement requested Dr. Chan (Director-General, WHO) to conduct an investigation of the leaks of documents of the WHO Expert Working Group on R&D Financing to the IFPMA. In its statement, Thailand noted that the circle of trust had been broken.
Mr. Chairman,I thank Madame DG to her explanation about the process and documentations including her constructive advices
Test Data
Misc links:
How to Calculate Standard Patent Expiry Dates and Data Exclusivity in Key Territories
Internal links